Impact of CYP2C19 Genotype-guided Approach in Antiplatelet Therapy on Platelet Reactivity Index Among Coronary Artery Disease (CAD) Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 120 participants.

Also called NCT06759272

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose health services research
Phase
Phase 4
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Nur Hafizah Annezah binti Utuh (from the registry)
Registry
  • NCT NCT06759272
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Malaysia (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06759272. Randomized; single masking; primary purpose health services research. Start 2025-02 (anticipated); primary completion 2026-02 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Impact of CYP2C19 Genotype-guided Approach in Antiplatelet Therapy on Platelet Reactivity Index Among Coronary Artery Disease (CAD) Patients
Condition
Coronary Arterial Disease (CAD (coronary artery disease))
Condition
ACS (Acute Coronary Syndrome)
Condition
SCAD
Intervention (Genetic)
CYP2C19 genotype-guided antiplatelet therapy
Lead sponsor
Nur Hafizah Annezah binti Utuh (class: other)

Record details

Record id
cardio:ct-nct06759272
Content hash
730473f0f93e9047277b2549173a55b8ab7db2b761d8ad5c099e4d2b0fe1dbac